Business and Finance

Cost-cutting will continue while marketplace demands a higher level of data quality from pharma

First of many meetings to come that are required by the Drug Supply Chain Security Act

Ernst & Young Firepower report sees a 'growth gap' for traditional pharmacos

Company's integration of Medco is 'largely complete'

Competitive forces sharpen as manufacturers look for the right channel partners

HDMA's 2013-14 Factbook updates member financial, operational performance

Will 'white bagging' and specialty-pharmacy business practices change distribution dynamics?

Growth includes 1-4% CAGR in US, 0-3% in Europe and 14-17% in China. US specialties have a twist

Both Revitas and Model N bring out enhanced script-validation modules to ensure rebate accuracy

New approaches, and new skill sets are necessary for meeting the challenges of global drug reimbursement policies

State-by-state, plan-by-plan analysis from CVS Caremark highlights multibillion-dollar savings if adherence rates are improved

Disconnected business processes in contract administration, managed markets, rebates, sales compensation and related areas cause waste and inefficiency for company management

For global markets, there is a need to balance the imperative to get to market quickly against the evolving regulatory landscape

Following its pathbreaking alliance with Walgreens/Alliance Boots, AmerisourceBergen is busy executing its future plans

More emphasis on digital technologies and overall cost reduction are on the wish list

Manufacturers are committing capital dollars to packaging-line enhancements; but will the rest of the supply chain be ready by 2015?

Annual Jones Lang LaSalle report ranks US clusters, looks at international activity

Patients, physicians and pharmacists signal their support of copay cards in Alliance Life Sciences study

PwC's annual analysis sees bright spots in R&D practices, while global economic troubles will constrain healthcare spending

Peer-reviewed study correlates adverse drug events (ADEs) with form of drug administration; can pharma manufacturers help?

New study magnifies the lost opportunity for industry eighteen-fold; the global gap is $564 billion

The new insurance exchanges are bound to impact industry rebates - and therefore the ability to manage financial reporting, says PwC Health Research Institute